Project Grant R01GM160387
- The National Institute of General Medical Sciences awarded $2,843,142 to Battelle Memorial Institute's Pacific Northwest National Laboratory on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a next-generation ultra-high resolution ion mobility spectrometer platform for metabolomics research. The project will deliver an ion mobility spectrometer with ultra-high resolution and sensitivity to detect small changes in metabolite structure, coupled...
- The National Institute of General Medical Sciences awarded Battelle Memorial Institute's Pacific Northwest National Laboratory $492,167 on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a high-throughput multiomic platform for simultaneous single-cell profiling of proteins, transcripts, and metabolites. The platform integrates novel chemistry, advanced mass spectrometry, and automated nanodroplet processing to analyze thousands of individual...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Brigham Young University $406,576 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an analytical platform for simultaneous separation, identification, and quantification of lipid isomers using non-covalent chemistry-based enhancement of tandem ion mobility-mass spectrometry. The research integrates...
- The National Institute of General Medical Sciences awarded the University of North Carolina at Greensboro $1.329 million on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop cost-effective workflows for unsaturated lipidomics analysis. The recipient will extend a novel ion chemistry called OZNOXESI beyond phospholipids to all lipid classes, particularly glycerolipids and sphingolipids, enabling determination of carbon-carbon double bond (C=C)...
- The National Institute of General Medical Sciences awarded $565,993 to Regents of the University of Michigan on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop next-generation native ion mobility-mass spectrometry (NIM-MS) methods for characterizing biotherapeutics, including protein and nucleic acid therapeutics. The project focuses on creating rapid, droplet-based enzymatic chemistries and collision-induced unfolding (CIU) approaches to assess...
- The National Institute of General Medical Sciences awarded the University of Virginia $1.708 million on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to define the paralipidome and establish how local lipid nano-environments around membrane proteins regulate their structure and physiology. The project, titled "Defining the Paralipidome: A New Frontier in Membrane Biology," will employ recent technical advances to directly probe the local...
- The National Institute of General Medical Sciences awarded Yale University $304,970 under the Biomedical Research and Research Training program (CFDA 93.859) on June 1, 2026, to develop next-generation mass spectrometry platforms for analyzing membrane protein complexes and their lipid environments at molecular and nanoscale resolution. The award funds three independent projects. Project 1 develops a native mass spectrometry platform to capture heteromeric complexes of membrane and soluble...
- The National Institute of General Medical Sciences awarded The Johns Hopkins University $133,515 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a multi-omic mass spectrometry imaging platform for visualizing inflammatory disease biomarkers in tissue sections. The funded work addresses technical limitations in current matrix-assisted laser desorption/ionization mass spectrometry imaging approaches by developing optimized protocols and...
- The National Institute of General Medical Sciences awarded Washington State University $406,037 in project grant funding on April 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance ion mobility spectrometry and mass spectrometry techniques for resolving isomeric and conformational features of biomolecules. The Clowers Research Group at Washington State University is developing Structures for Lossless Ion Manipulations (SLIM) technology integrated with...
- The National Institute of General Medical Sciences awarded the University of Florida $1,892,969 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop novel mass spectrometry technologies for high-resolution molecular imaging of tissue samples. The research addresses critical deficiencies in imaging mass spectrometry (IMS) by advancing chemistries and next-generation analytical techniques that improve both chemical differentiation and spatial...
The National Institute of General Medical Sciences awarded $1.688 million to Pacific Northwest National Laboratory, a division of Battelle Memorial Institute, on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a multimodal measurement platform for unambiguous lipid identification. The recipient will build a high-resolution ion mobility-mass spectrometry (IM-MS) system designed to distinguish free fatty acids and lipid isomers in complex biomedical samples. The platform combines a novel traveling-cups ion mobility module (cupped IMS) to separate structurally similar lipid isomers with collision cross-section measurements, and ultraviolet photodissociation capability integrated into an Orbitrap mass spectrometer to identify the locations of lipid double bonds along alkyl chains. High-resolution mass measurements from the Orbitrap will derive chemical formulae for lipids and free fatty acids. The system addresses a gap in lipidomics research by unambiguously characterizing lipid signatures whose biomedical activities remain unknown due to current analytical technology's inability to distinguish isomers. The award covers the period from August 1, 2026, through July 31, 2030, with place of performance in Washington. NIGMS supports basic research that increases understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 7/29/26 |